USPTO serial 79227076
HEC
Reviewed by CopyMark Law Group
Reg. 5736027Status 706Registered
- Filing date
- Status date
- Registration date
- Apr 30, 2019
- Examiner
- GAYNOR, BARBARA ANNE
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with HEC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Yichang HEC Changjiang Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Yichang HEC Changjiang Pharmaceutical Co., Ltd.
Yichang HEC Changjiang Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Yichang HEC Changjiang Pharmaceutical Co., Ltd.
Yichang HEC Changjiang Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Yichang HEC Changjiang Pharmaceutical Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nazly Aileen Bayramoglu
Nazly Aileen Bayramoglu Baryramoglu Law Offices LLC1540 West Warm Springs Road Suite 100Henderson, NV 89014United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for human purposes for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders, cancer, inflammation, dermal diseases, heart diseases, respiratory diseases and disorders, gastrointestinal diseases, infectious diseases, bone diseases, circulatory disease, cerebral diseases and articular rheumatism; Medicines for human purposes, namely, anti-infectives and antivirals; Pharmaceutical preparations for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Pharmaceutical preparations, namely, anti-infectives and antivirals; Pharmaceutical preparations for the treatment of cough, cold and flu symptoms; adjuvants for medical purposes; Bulk drug in the nature of a pharmaceutical preparation for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Bulk drug in the nature of a pharmaceutical preparation, namely, anti-infectives and antivirals; Bulk drug in the nature of a pharmaceutical preparation for the treatment of hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese patent medicines, for use in the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Chinese patent medicines, namely, anti-infectives and antivirals; Chinese patent medicines, for use in the treatment of traumatic injuries, bleeding wounds, gynecological diseases, epistaxis, bronchial dilating, pulmonary tuberculosis, pneumonia, gastrointestinal tract hemorrhage, anti-inflammation, healing of a wound, chilblain, help healing of fracture, motor impairment, pain from rheumatism, injury of bones, joints and soft tissue, mosquito and insect bites, swelling and pain due to blood stasis, and lumbar muscle strain; Biochemical medicines for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Biochemical medicines, namely, anti-infectives and antivirals; Biochemical medicines for the treatment of pneumonia, urinary tract infection, gynecological infections, skin and skin structure infections, meningitis, septicemia, cancer, diabetes, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Medicinal infusions for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Medicinal infusions, namely, anti-infectives and antivirals; Medicinal infusions for the treatment of epilepsy, convulsions, seizures, pain, multiple sclerosis, neuropathic pain, spinal cord injury, bladder disfunction, peripheral neuropathy, cancer pain, peri-operative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, obesity, obesity associated with type 2 diabetes, bulimia, schizophrenia, crohn's disease, alzheimer's disease, bone disorders, hypoxic-ischaemic encephalopathy, drug, alcohol and nicotine abuse and inflammatory disorders; diagnostic preparations for medical purposes; gases for medical purposes; chemical conductors for electrocardiograph electrodes; contact lens cleaning preparations; Nutritive substances for microorganisms for medical purposes; disinfectants; food for babies; infant milk powder; depuratives for the body; Veterinary preparations for horses, dogs, and cats for the prevention and treatment of pain, illness, and fatigue; Medicine health bag being medicinal herbs for general health and well-being contained in a small bag; Decoctions for pharmaceutical purposes for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Decoctions for pharmaceutical purposes, namely, anti-infectives and antivirals; Decoctions for pharmaceutical purposes for treatment of immune disorders; Drugs for medical purposes, namely, for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, ocular, reproductive, circulatory, digestive, ear, blood, psychiatric, behavioral, nervous, and immune system related diseases and disorders; Drugs for medical purposes, namely, anti-infectives and antivirals; Medical hemostatic paste; medicinal herbs; Transdermal patches for use in the temporary relief of headache and muscle pain; medicinal tea; Allergy capsules; soporifics; Biological preparations for medical purposes, namely, for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Biological preparations for medical purposes, namely, anti-infectives and antivirals; medical preparations for slimming purposes; medicinal wine; poultices; Medicine cases, portable, filled, namely, first aid kits; Medicinal oil; Liquid medicines for the treatment of digestive system disorders, cardiovascular disorders, nervous system disorders, metabolic system disorders and dermal diseases; Liquid medicines, namely, anti-infectives and antivirals; Liquid medicines for treating colds; Medicines for veterinary purposes for treating and preventing infections caused by bacteria or parasites in companion and food producing animals; surgical dressings; solutions for contact lenses | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Yichang HEC Changjiang Pharmaceutical Co., Ltd.
- Other trademarks owned by Yichang HEC Changjiang Pharmaceutical Co., Ltd.
- Other trademarks owned by Yichang HEC Changjiang Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named HEC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 22, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jul 22, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 22, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 22, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 21, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jul 21, 2025 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Jul 15, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 21, 2025 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Apr 30, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 11, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 16, 2019 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Aug 16, 2019 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jul 30, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 30, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 18, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 18, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 12, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 8, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 23, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 23, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 23, 2019 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 8, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 19, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 19, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 17, 2018 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 13, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 13, 2018 | ALIE | ASSIGNED TO LIE | — |
| Dec 11, 2018 | NREV | NOTICE OF REVIVAL - MAILED | — |
| Dec 10, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 10, 2018 | PETG | PETITION TO REVIVE-GRANTED | — |
| Dec 10, 2018 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Oct 11, 2018 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 11, 2018 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 30, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 15, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 15, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 10, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 9, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 27, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 15, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |